Compare Becton Dickinson and Co (BDX) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares MSCI South Korea ETF — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while iShares MSCI South Korea ETF trades at $171.64. The key difference: Becton Dickinson and Co pays a 2.34% dividend while iShares MSCI South Korea ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| BDX | EWY | |
|---|---|---|
Market Cap | $48.93B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $219.20 |
52-Week Low | $138.62 | $71.22 |
Enterprise Value | $65.03B | — |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
EWY (iShares MSCI South Korea ETF) trades at $166.09, up 1.2% with a neutral technical signal. The ETF faces volatility from South Korea's AI and semiconductor exposure, with recent news highlighting both government support initiatives and significant market swings. Technical indicators show mixed signals with RSI at 75.01 suggesting overbought conditions while moving averages remain bullish.
The outlook remains cautious as South Korean equities navigate AI-driven volatility and regulatory changes. Goldman Sachs maintains strong conviction with 90% upside potential for Korean stocks, but recent ETF speculation curbs and semiconductor stock declines present near-term headwinds for EWY investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
